Preview: Syros Pharmaceuticals's Earnings
Portfolio Pulse from Benzinga Insights
Syros Pharmaceuticals (NASDAQ:SYRS) is expected to release its quarterly earnings report on Tuesday, 2023-11-14, with an estimated EPS of $-1.14. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, the company's stock price has been affected more by guidance than by earnings beats or misses. Last quarter, SYRS missed the EPS estimate by $0.17, resulting in a 1.91% increase in share price the following day. Over the last year, SYRS shares have declined by 30.17%, indicating a bearish sentiment among long-term shareholders.
November 13, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Syros Pharmaceuticals is anticipated to report quarterly earnings with investors focusing on potential earnings beat and future guidance. Historical data shows guidance impacts stock price more than earnings results. Long-term trend shows a 30.17% decline in share price.
The short-term impact on SYRS stock will likely hinge on whether the company beats the earnings estimate and provides positive guidance. Historical performance suggests that guidance has a significant impact on the stock price. However, the long-term downward trend may temper any positive reaction to an earnings beat.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100